Jelena Klawitter
Concepts (535)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 15 | 2025 | 266 | 4.360 |
Why?
| | Metabolomics | 21 | 2025 | 702 | 3.020 |
Why?
| | Kidney | 21 | 2025 | 1475 | 2.670 |
Why?
| | Tandem Mass Spectrometry | 16 | 2025 | 568 | 2.600 |
Why?
| | Cardiopulmonary Bypass | 10 | 2025 | 217 | 2.190 |
Why?
| | Immunosuppressive Agents | 15 | 2019 | 854 | 1.820 |
Why?
| | Chromatography, High Pressure Liquid | 14 | 2024 | 593 | 1.790 |
Why?
| | Oxidative Stress | 18 | 2020 | 1325 | 1.660 |
Why?
| | Cyclosporine | 10 | 2019 | 265 | 1.640 |
Why?
| | Metabolome | 9 | 2025 | 366 | 1.340 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 442 | 1.220 |
Why?
| | Sirolimus | 9 | 2019 | 276 | 1.110 |
Why?
| | Kidney Transplantation | 11 | 2025 | 677 | 1.050 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.040 |
Why?
| | Cardiac Surgical Procedures | 3 | 2022 | 587 | 1.040 |
Why?
| | Biomarkers | 23 | 2025 | 4175 | 0.990 |
Why?
| | Energy Metabolism | 8 | 2022 | 930 | 0.920 |
Why?
| | Proteomics | 14 | 2020 | 1136 | 0.920 |
Why?
| | Pravastatin | 4 | 2025 | 45 | 0.910 |
Why?
| | Acute Kidney Injury | 3 | 2022 | 820 | 0.910 |
Why?
| | Allografts | 1 | 2025 | 147 | 0.890 |
Why?
| | Tryptophan | 5 | 2024 | 179 | 0.870 |
Why?
| | Tacrolimus | 5 | 2025 | 198 | 0.760 |
Why?
| | TRPP Cation Channels | 2 | 2024 | 81 | 0.760 |
Why?
| | Kynurenine | 5 | 2024 | 115 | 0.750 |
Why?
| | Endocannabinoids | 4 | 2025 | 68 | 0.750 |
Why?
| | Endothelium, Vascular | 5 | 2021 | 949 | 0.740 |
Why?
| | Lovastatin | 2 | 2013 | 38 | 0.720 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2025 | 449 | 0.720 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 562 | 0.700 |
Why?
| | Menopause | 3 | 2020 | 317 | 0.680 |
Why?
| | Arginine | 2 | 2024 | 257 | 0.670 |
Why?
| | Cannabinoids | 3 | 2024 | 178 | 0.660 |
Why?
| | Heart Defects, Congenital | 5 | 2025 | 879 | 0.640 |
Why?
| | Mass Spectrometry | 10 | 2021 | 740 | 0.640 |
Why?
| | Glomerular Filtration Rate | 11 | 2025 | 752 | 0.640 |
Why?
| | Myocardium | 2 | 2017 | 927 | 0.630 |
Why?
| | Kidney Failure, Chronic | 2 | 2025 | 599 | 0.620 |
Why?
| | Signal Transduction | 11 | 2021 | 5148 | 0.590 |
Why?
| | Coronary Care Units | 1 | 2018 | 23 | 0.590 |
Why?
| | Adenosine | 3 | 2018 | 253 | 0.590 |
Why?
| | Piperazines | 3 | 2009 | 371 | 0.570 |
Why?
| | Pyrimidines | 4 | 2014 | 508 | 0.560 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 32 | 0.540 |
Why?
| | Urine | 1 | 2017 | 62 | 0.530 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 30 | 0.520 |
Why?
| | Alkaline Phosphatase | 2 | 2018 | 149 | 0.510 |
Why?
| | Mycophenolic Acid | 3 | 2014 | 118 | 0.500 |
Why?
| | Length of Stay | 4 | 2025 | 1259 | 0.500 |
Why?
| | Male | 53 | 2025 | 69893 | 0.500 |
Why?
| | Disease Models, Animal | 9 | 2024 | 4407 | 0.480 |
Why?
| | Animals | 42 | 2024 | 37579 | 0.480 |
Why?
| | Adenosine Monophosphate | 1 | 2016 | 73 | 0.480 |
Why?
| | Plasma | 1 | 2017 | 222 | 0.480 |
Why?
| | Female | 51 | 2025 | 75540 | 0.470 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 268 | 0.470 |
Why?
| | Isoprostanes | 3 | 2012 | 15 | 0.450 |
Why?
| | Humans | 74 | 2025 | 140898 | 0.450 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 324 | 0.450 |
Why?
| | Disease Progression | 8 | 2025 | 2791 | 0.440 |
Why?
| | Limit of Detection | 7 | 2024 | 94 | 0.430 |
Why?
| | Chromatography, Liquid | 8 | 2024 | 453 | 0.430 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.420 |
Why?
| | Endothelium | 1 | 2014 | 127 | 0.420 |
Why?
| | Kidney Diseases | 4 | 2021 | 408 | 0.420 |
Why?
| | Oxylipins | 2 | 2025 | 41 | 0.410 |
Why?
| | Cell Proliferation | 4 | 2024 | 2497 | 0.410 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 124 | 0.400 |
Why?
| | Inflammation | 9 | 2025 | 2891 | 0.400 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 7 | 0.390 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.380 |
Why?
| | Proteome | 3 | 2016 | 483 | 0.380 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 73 | 0.380 |
Why?
| | Oncogene Proteins | 1 | 2012 | 63 | 0.370 |
Why?
| | Dinoprost | 5 | 2019 | 46 | 0.370 |
Why?
| | Mutation | 2 | 2022 | 3999 | 0.370 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 851 | 0.360 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 281 | 0.350 |
Why?
| | Rats | 16 | 2024 | 5594 | 0.350 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 162 | 0.350 |
Why?
| | Plant Extracts | 2 | 2024 | 210 | 0.350 |
Why?
| | Nitric Oxide | 4 | 2024 | 897 | 0.340 |
Why?
| | Mitochondria | 1 | 2017 | 974 | 0.340 |
Why?
| | Postoperative Complications | 3 | 2021 | 2813 | 0.340 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 280 | 0.330 |
Why?
| | Purines | 2 | 2022 | 182 | 0.330 |
Why?
| | Blotting, Western | 6 | 2012 | 1231 | 0.320 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 614 | 0.320 |
Why?
| | Hypoxia | 6 | 2024 | 1164 | 0.320 |
Why?
| | Mice, Inbred C57BL | 12 | 2023 | 5895 | 0.310 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 466 | 0.310 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 340 | 0.310 |
Why?
| | Prostaglandins | 3 | 2022 | 101 | 0.300 |
Why?
| | Ureteral Obstruction | 2 | 2021 | 64 | 0.300 |
Why?
| | Theophylline | 2 | 2020 | 43 | 0.300 |
Why?
| | Autophagy | 3 | 2024 | 284 | 0.300 |
Why?
| | Glycolysis | 4 | 2012 | 326 | 0.300 |
Why?
| | Mice | 19 | 2024 | 18057 | 0.290 |
Why?
| | Infant | 10 | 2025 | 9790 | 0.290 |
Why?
| | Antineoplastic Agents | 3 | 2009 | 2156 | 0.290 |
Why?
| | Arachidonate 12-Lipoxygenase | 2 | 2021 | 18 | 0.290 |
Why?
| | Arachidonate 15-Lipoxygenase | 2 | 2021 | 23 | 0.290 |
Why?
| | Mice, Knockout | 7 | 2023 | 3064 | 0.280 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3487 | 0.270 |
Why?
| | Vascular Diseases | 2 | 2021 | 244 | 0.270 |
Why?
| | Amino Acids | 2 | 2025 | 493 | 0.270 |
Why?
| | Case-Control Studies | 7 | 2024 | 3578 | 0.270 |
Why?
| | Blood Vessels | 2 | 2019 | 180 | 0.260 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2009 | 832 | 0.260 |
Why?
| | Prospective Studies | 13 | 2025 | 7749 | 0.260 |
Why?
| | Reproducibility of Results | 11 | 2024 | 3336 | 0.260 |
Why?
| | Time Factors | 8 | 2022 | 6944 | 0.250 |
Why?
| | Infant, Newborn | 8 | 2025 | 6257 | 0.250 |
Why?
| | Rats, Wistar | 6 | 2018 | 451 | 0.240 |
Why?
| | Microsomes, Liver | 2 | 2019 | 81 | 0.240 |
Why?
| | Deoxyglucose | 2 | 2024 | 51 | 0.230 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2235 | 0.230 |
Why?
| | Child | 10 | 2025 | 22313 | 0.230 |
Why?
| | Swine | 3 | 2022 | 809 | 0.230 |
Why?
| | Treatment Outcome | 9 | 2025 | 11125 | 0.230 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 74 | 0.230 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.230 |
Why?
| | Mitragyna | 1 | 2024 | 7 | 0.220 |
Why?
| | Alkaloids | 1 | 2024 | 28 | 0.220 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 70 | 0.220 |
Why?
| | Young Adult | 12 | 2023 | 13646 | 0.220 |
Why?
| | Dronabinol | 2 | 2024 | 240 | 0.210 |
Why?
| | Transplantation, Homologous | 1 | 2025 | 415 | 0.210 |
Why?
| | Adolescent | 10 | 2025 | 22027 | 0.210 |
Why?
| | Glycerides | 1 | 2024 | 21 | 0.210 |
Why?
| | Citrulline | 1 | 2024 | 44 | 0.210 |
Why?
| | Arachidonic Acids | 1 | 2024 | 62 | 0.210 |
Why?
| | Adult | 18 | 2025 | 39134 | 0.210 |
Why?
| | Graft Rejection | 4 | 2017 | 546 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 40 | 0.200 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 26 | 0.200 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2012 | 111 | 0.190 |
Why?
| | Analgesia | 1 | 2024 | 102 | 0.190 |
Why?
| | Tissue Distribution | 2 | 2014 | 327 | 0.190 |
Why?
| | Cytokines | 5 | 2025 | 2092 | 0.190 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 27 | 0.180 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 582 | 0.180 |
Why?
| | Double-Blind Method | 6 | 2025 | 1978 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.180 |
Why?
| | Nephritis | 1 | 2021 | 24 | 0.180 |
Why?
| | Aminophylline | 2 | 2020 | 12 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2021 | 517 | 0.180 |
Why?
| | Middle Aged | 17 | 2025 | 34487 | 0.180 |
Why?
| | Fetal Diseases | 1 | 2023 | 180 | 0.180 |
Why?
| | Curcumin | 1 | 2021 | 28 | 0.180 |
Why?
| | Vascular Stiffness | 3 | 2021 | 449 | 0.180 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 306 | 0.180 |
Why?
| | Indoles | 1 | 2025 | 475 | 0.170 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 79 | 0.170 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 47 | 0.170 |
Why?
| | Calcium Channels, T-Type | 1 | 2022 | 105 | 0.170 |
Why?
| | Hypothalamus | 2 | 2018 | 154 | 0.170 |
Why?
| | Niacinamide | 1 | 2021 | 82 | 0.170 |
Why?
| | Databases, Genetic | 1 | 2022 | 243 | 0.170 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 123 | 0.160 |
Why?
| | Methionine | 1 | 2021 | 159 | 0.160 |
Why?
| | Organ Size | 2 | 2025 | 477 | 0.160 |
Why?
| | Benzamides | 3 | 2009 | 220 | 0.160 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2020 | 41 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 415 | 0.160 |
Why?
| | Nephrectomy | 1 | 2021 | 156 | 0.160 |
Why?
| | Cannabidiol | 1 | 2022 | 126 | 0.160 |
Why?
| | Pain | 1 | 2025 | 776 | 0.160 |
Why?
| | Vasodilation | 3 | 2018 | 516 | 0.160 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 92 | 0.150 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 18 | 0.150 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 67 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 86 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 36 | 0.150 |
Why?
| | Bone Marrow | 2 | 2017 | 301 | 0.150 |
Why?
| | Vitamin D | 2 | 2019 | 392 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 33 | 0.150 |
Why?
| | Brain | 2 | 2013 | 2852 | 0.150 |
Why?
| | Glucose | 2 | 2017 | 1031 | 0.140 |
Why?
| | Blood Proteins | 1 | 2020 | 250 | 0.140 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 55 | 0.140 |
Why?
| | Homocysteine | 1 | 2019 | 154 | 0.140 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2020 | 182 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 331 | 0.140 |
Why?
| | DNA Damage | 2 | 2019 | 429 | 0.140 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2018 | 263 | 0.140 |
Why?
| | Group IV Phospholipases A2 | 1 | 2017 | 47 | 0.140 |
Why?
| | Phenylpropionates | 1 | 2017 | 21 | 0.140 |
Why?
| | Phenotype | 3 | 2022 | 3172 | 0.140 |
Why?
| | 5'-Nucleotidase | 1 | 2018 | 47 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 208 | 0.140 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 329 | 0.130 |
Why?
| | Complement Factor B | 1 | 2018 | 110 | 0.130 |
Why?
| | Terbutaline | 1 | 2017 | 9 | 0.130 |
Why?
| | Endothelins | 1 | 2017 | 63 | 0.130 |
Why?
| | Sex Characteristics | 2 | 2013 | 785 | 0.130 |
Why?
| | Cell Cycle | 2 | 2011 | 598 | 0.130 |
Why?
| | Pyridazines | 1 | 2017 | 56 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 121 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 93 | 0.130 |
Why?
| | Protein Kinases | 2 | 2017 | 308 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 79 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 720 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 150 | 0.130 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2018 | 195 | 0.130 |
Why?
| | Receptors, Calcitriol | 1 | 2017 | 55 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 183 | 0.130 |
Why?
| | Glutamic Acid | 1 | 2018 | 256 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2018 | 287 | 0.130 |
Why?
| | Brachial Artery | 4 | 2019 | 204 | 0.120 |
Why?
| | Calcineurin Inhibitors | 2 | 2014 | 70 | 0.120 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.120 |
Why?
| | Drug Synergism | 2 | 2014 | 369 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1178 | 0.120 |
Why?
| | Breast | 1 | 2017 | 155 | 0.120 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.120 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2013 | 100 | 0.120 |
Why?
| | Helminth Proteins | 1 | 2016 | 26 | 0.120 |
Why?
| | Extracellular Space | 1 | 2016 | 129 | 0.120 |
Why?
| | Solubility | 1 | 2016 | 244 | 0.120 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| | Linoleic Acids | 1 | 2015 | 7 | 0.120 |
Why?
| | Transplant Recipients | 1 | 2017 | 181 | 0.120 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 44 | 0.120 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.120 |
Why?
| | Premature Birth | 1 | 2019 | 363 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2062 | 0.120 |
Why?
| | Enzyme Activation | 1 | 2017 | 801 | 0.120 |
Why?
| | Therapeutic Equivalency | 2 | 2017 | 32 | 0.120 |
Why?
| | Fishes | 1 | 2016 | 109 | 0.120 |
Why?
| | Chi-Square Distribution | 1 | 2016 | 521 | 0.110 |
Why?
| | Postoperative Period | 1 | 2016 | 360 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2019 | 406 | 0.110 |
Why?
| | Reperfusion Injury | 1 | 2018 | 292 | 0.110 |
Why?
| | Diet, Sodium-Restricted | 1 | 2015 | 38 | 0.110 |
Why?
| | Aerosols | 1 | 2016 | 180 | 0.110 |
Why?
| | Biological Availability | 2 | 2017 | 137 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2016 | 649 | 0.110 |
Why?
| | Serine | 1 | 2015 | 148 | 0.110 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 163 | 0.110 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 444 | 0.110 |
Why?
| | DNA Methylation | 1 | 2019 | 640 | 0.110 |
Why?
| | Child, Preschool | 3 | 2025 | 11462 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2018 | 923 | 0.110 |
Why?
| | Macrophages, Alveolar | 2 | 2016 | 395 | 0.110 |
Why?
| | Tidal Volume | 1 | 2014 | 102 | 0.110 |
Why?
| | Cannabis | 1 | 2021 | 510 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 24 | 0.100 |
Why?
| | Cattle | 1 | 2016 | 991 | 0.100 |
Why?
| | Respiration, Artificial | 2 | 2018 | 685 | 0.100 |
Why?
| | Aging | 2 | 2015 | 1917 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2018 | 317 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1313 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 332 | 0.100 |
Why?
| | Everolimus | 2 | 2012 | 110 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 108 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2051 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Lung | 3 | 2022 | 4127 | 0.100 |
Why?
| | Reactive Oxygen Species | 3 | 2012 | 632 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2368 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 387 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 57 | 0.100 |
Why?
| | Pilot Projects | 4 | 2023 | 1815 | 0.100 |
Why?
| | Cytoprotection | 1 | 2012 | 57 | 0.100 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 15 | 0.100 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 75 | 0.100 |
Why?
| | Ion Transport | 1 | 2012 | 62 | 0.100 |
Why?
| | K562 Cells | 2 | 2009 | 95 | 0.100 |
Why?
| | Gluconeogenesis | 1 | 2012 | 78 | 0.090 |
Why?
| | Nicorandil | 1 | 2012 | 11 | 0.090 |
Why?
| | Glutamine | 1 | 2012 | 107 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5645 | 0.090 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 21 | 0.090 |
Why?
| | Integrins | 1 | 2012 | 95 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2018 | 813 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 136 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2898 | 0.090 |
Why?
| | Regression Analysis | 2 | 2012 | 1015 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 622 | 0.090 |
Why?
| | Androgens | 1 | 2013 | 187 | 0.090 |
Why?
| | Phosphates | 1 | 2012 | 179 | 0.090 |
Why?
| | Glucuronides | 1 | 2011 | 19 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Lung Injury | 1 | 2014 | 227 | 0.090 |
Why?
| | Cytoskeleton | 1 | 2012 | 194 | 0.090 |
Why?
| | Aged | 7 | 2025 | 24666 | 0.090 |
Why?
| | Fatty Acids | 1 | 2014 | 448 | 0.090 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 199 | 0.090 |
Why?
| | Age Factors | 1 | 2018 | 3278 | 0.090 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.090 |
Why?
| | Models, Animal | 1 | 2013 | 393 | 0.090 |
Why?
| | Artifacts | 1 | 2011 | 133 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2017 | 768 | 0.080 |
Why?
| | Serotonin | 2 | 2024 | 310 | 0.080 |
Why?
| | Cell Survival | 2 | 2012 | 1129 | 0.080 |
Why?
| | Citric Acid Cycle | 1 | 2010 | 58 | 0.080 |
Why?
| | Drugs, Generic | 1 | 2010 | 25 | 0.080 |
Why?
| | Cross Reactions | 1 | 2010 | 133 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 367 | 0.080 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2007 | 181 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 99 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2014 | 1195 | 0.080 |
Why?
| | Brain Ischemia | 1 | 2013 | 349 | 0.080 |
Why?
| | Drug Approval | 1 | 2010 | 87 | 0.080 |
Why?
| | Heart Ventricles | 2 | 2024 | 749 | 0.080 |
Why?
| | Reference Standards | 1 | 2009 | 185 | 0.080 |
Why?
| | Risk Assessment | 1 | 2018 | 3484 | 0.080 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 47 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2013 | 4199 | 0.070 |
Why?
| | Oncogenes | 1 | 2009 | 118 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1761 | 0.070 |
Why?
| | Lysosomes | 2 | 2021 | 147 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1968 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2012 | 293 | 0.070 |
Why?
| | Cross-Over Studies | 3 | 2017 | 577 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 596 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1758 | 0.070 |
Why?
| | Astrocytes | 1 | 2010 | 216 | 0.070 |
Why?
| | Phospholipids | 1 | 2009 | 221 | 0.070 |
Why?
| | Lactic Acid | 1 | 2009 | 303 | 0.070 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 21 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 525 | 0.070 |
Why?
| | Fibrosis | 2 | 2021 | 542 | 0.070 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 628 | 0.070 |
Why?
| | Apoptosis | 3 | 2012 | 2571 | 0.070 |
Why?
| | Food Hypersensitivity | 1 | 2010 | 182 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 174 | 0.060 |
Why?
| | Allergens | 1 | 2010 | 401 | 0.060 |
Why?
| | Nucleotides | 1 | 2007 | 127 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1113 | 0.060 |
Why?
| | Hydroxylation | 2 | 2019 | 45 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1251 | 0.060 |
Why?
| | Estradiol | 2 | 2020 | 523 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 411 | 0.060 |
Why?
| | Pulse Wave Analysis | 2 | 2018 | 237 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2108 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | Renal Circulation | 1 | 2025 | 72 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2024 | 428 | 0.060 |
Why?
| | Palliative Care | 2 | 2024 | 819 | 0.060 |
Why?
| | Kynurenic Acid | 1 | 2024 | 18 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1786 | 0.060 |
Why?
| | Isomerism | 1 | 2024 | 55 | 0.050 |
Why?
| | Blood Pressure | 3 | 2019 | 1745 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 2967 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10430 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2008 | 398 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1919 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1158 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 34 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3000 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 91 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 136 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2025 | 248 | 0.050 |
Why?
| | Morbidity | 1 | 2024 | 320 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 2 | 2013 | 54 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 34 | 0.050 |
Why?
| | Androstanols | 1 | 2022 | 22 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 57 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1038 | 0.050 |
Why?
| | Urinalysis | 2 | 2015 | 77 | 0.050 |
Why?
| | Drug Interactions | 2 | 2017 | 403 | 0.050 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2021 | 40 | 0.050 |
Why?
| | Steroids | 1 | 2022 | 163 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2879 | 0.040 |
Why?
| | Nitriles | 1 | 2022 | 188 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 141 | 0.040 |
Why?
| | Pregnancy | 3 | 2019 | 7035 | 0.040 |
Why?
| | Rats, Inbred Lew | 2 | 2012 | 105 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 91 | 0.040 |
Why?
| | Drug Stability | 2 | 2011 | 165 | 0.040 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 78 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 85 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 62 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 162 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2020 | 31 | 0.040 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2020 | 25 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2022 | 214 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 5789 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 131 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 306 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 150 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 143 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 1271 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.040 |
Why?
| | Molecular Structure | 2 | 2014 | 501 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 80 | 0.040 |
Why?
| | Pulmonary Veins | 1 | 2020 | 106 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 63 | 0.040 |
Why?
| | Administration, Oral | 2 | 2012 | 802 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1269 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 89 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 156 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Reference Values | 2 | 2013 | 803 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 490 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 184 | 0.040 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 38 | 0.040 |
Why?
| | Complement C5a | 1 | 2018 | 71 | 0.040 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2018 | 24 | 0.030 |
Why?
| | Rewarming | 1 | 2018 | 21 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2018 | 78 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2176 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1598 | 0.030 |
Why?
| | Position-Specific Scoring Matrices | 1 | 2017 | 2 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 187 | 0.030 |
Why?
| | Femoral Artery | 1 | 2018 | 184 | 0.030 |
Why?
| | Birth Weight | 1 | 2020 | 511 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2018 | 201 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 144 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1022 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 289 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 369 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 540 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 308 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 134 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 65 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1086 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 225 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 42 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 357 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2056 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 598 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 477 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 691 | 0.030 |
Why?
| | Aldehydes | 1 | 2016 | 146 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 412 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 917 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 58 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 332 | 0.030 |
Why?
| | Safety | 1 | 2017 | 356 | 0.030 |
Why?
| | Larva | 1 | 2016 | 238 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 24 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 19 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 253 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 310 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2017 | 866 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 404 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 594 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 88 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1651 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 65 | 0.030 |
Why?
| | Prognosis | 2 | 2013 | 4060 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 56 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1496 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 96 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 3 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 13 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 134 | 0.030 |
Why?
| | Macrophages | 1 | 2021 | 1559 | 0.030 |
Why?
| | Binding Sites | 1 | 2017 | 1315 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 125 | 0.030 |
Why?
| | Dihydrotestosterone | 1 | 2013 | 44 | 0.030 |
Why?
| | Orchiectomy | 1 | 2013 | 74 | 0.020 |
Why?
| | Altitude | 1 | 2017 | 473 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2015 | 498 | 0.020 |
Why?
| | Cell Count | 1 | 2013 | 325 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2013 | 43 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 54 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 170 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 703 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 203 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 74 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 344 | 0.020 |
Why?
| | Streptozocin | 1 | 2012 | 22 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 197 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2013 | 153 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1100 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 173 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1811 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 197 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 248 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 587 | 0.020 |
Why?
| | Neuroprotective Agents | 1 | 2013 | 142 | 0.020 |
Why?
| | Transplantation | 1 | 2011 | 33 | 0.020 |
Why?
| | Podocytes | 1 | 2012 | 68 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 578 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 680 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2011 | 84 | 0.020 |
Why?
| | Methylation | 1 | 2011 | 230 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2238 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1430 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 285 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 196 | 0.020 |
Why?
| | Daucus carota | 1 | 2010 | 2 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 624 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2010 | 20 | 0.020 |
Why?
| | Buffers | 1 | 2010 | 56 | 0.020 |
Why?
| | Graft Survival | 1 | 2012 | 501 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 384 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 656 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 887 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 157 | 0.020 |
Why?
| | Hot Temperature | 1 | 2012 | 406 | 0.020 |
Why?
| | Antigens, Plant | 1 | 2010 | 54 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2374 | 0.020 |
Why?
| | Ribose | 1 | 2009 | 22 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1320 | 0.020 |
Why?
| | Plant Proteins | 1 | 2010 | 111 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1822 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 391 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 9 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 372 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 79 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 197 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 842 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 16315 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 136 | 0.020 |
Why?
| | Vegetables | 1 | 2010 | 161 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2009 | 143 | 0.020 |
Why?
| | Liver | 1 | 2016 | 1815 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2522 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 873 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 344 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 448 | 0.020 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 985 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2152 | 0.010 |
Why?
| | Genotype | 1 | 2011 | 1862 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2917 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2920 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4597 | 0.010 |
Why?
| | Neurons | 1 | 2013 | 1615 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 414 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 2604 | 0.010 |
Why?
| | United States | 1 | 2010 | 15195 | 0.010 |
Why?
|
|
Klawitter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|